Literature DB >> 3170105

Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones.

A Mitwalli1, A Ayiomamitis, L Grass, D G Oreopoulos.   

Abstract

Pyridoxine in doses of 250-500 mg daily by mouth was administered to 12 patients suffering from recurrent calcium oxalate renal calculi and idiopathic hyperoxaluria. This therapy decreased urinary oxalate excretion significantly (p less than 0.025) during up to 18 months of treatment. In that period eight patients showed no evidence of active stone disease; three showed slight increase in the size of their old stone(s) and one patient formed one new stone. None of these patients developed any significant complications of the therapy. These findings support the view that pyridoxine in pharmacological doses is useful in the control of elevated urinary oxalate excretion in patients with recurrent renal oxalate calculi.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170105     DOI: 10.1007/bf02549567

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  23 in total

1.  Vitamin B6 deficiency and oxalate nephrocalcinosis in the cat.

Authors:  S N GERSHOFF; F F FARAGALLA; D A NELSON; S B ANDRUS
Journal:  Am J Med       Date:  1959-07       Impact factor: 4.965

2.  Treatment of primary hyperoxaluria.

Authors:  L H Smith; H E Williams
Journal:  Mod Treat       Date:  1967-05

3.  Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi.

Authors:  E L Prien; S F Gershoff
Journal:  J Urol       Date:  1974-10       Impact factor: 7.450

4.  The action of pyridoxine in primary hyperoxaluria.

Authors:  D A Gibbs; R W Watts
Journal:  Clin Sci       Date:  1970-02       Impact factor: 6.124

5.  Treatment of primary hyperoxaluria.

Authors:  C E Dent; T C Stamp
Journal:  Arch Dis Child       Date:  1970-12       Impact factor: 3.791

6.  The evaluation of some biochemical parameters in pyridoxine-treated calcium oxalate renal stone formers.

Authors:  V Revúsová; J Gratzlová; V Zvara; J Kridl; B Suchánek; J Breza
Journal:  Urol Int       Date:  1977       Impact factor: 2.089

7.  The influence of oestrogens on tryptophan metabolism in man.

Authors:  D P Rose
Journal:  Clin Sci       Date:  1966-10       Impact factor: 6.124

8.  Studies on some possible biochemical treatments of primary hyperoxaluria.

Authors:  R W Watts; R A Chalmers; D A Gibbs; A M Lawson; P Purkiss; E Spellacy
Journal:  Q J Med       Date:  1979-04

9.  Primary oxalosis: clinical and biochemical response to high-dose pyridoxine therapy.

Authors:  E J Will; O L Bijvoet
Journal:  Metabolism       Date:  1979-05       Impact factor: 8.694

10.  The diurnal urinary excretion of oxalate and the effect of pyridoxine and ascorbate on oxalate excretion.

Authors:  H G Tiselius; L E Almgård
Journal:  Eur Urol       Date:  1977       Impact factor: 20.096

View more
  8 in total

Review 1.  Stone formation and management after bariatric surgery.

Authors:  Sarah Tarplin; Vishnu Ganesan; Manoj Monga
Journal:  Nat Rev Urol       Date:  2015-04-07       Impact factor: 14.432

2.  Effect of blind treatment on stone disease.

Authors:  Y M Fazil Marickar; Abiya Salim; Adarsh Vijay
Journal:  Urol Res       Date:  2009-12-08

Review 3.  Nephropathy in dietary hyperoxaluria: A potentially preventable acute or chronic kidney disease.

Authors:  Robert H Glew; Yijuan Sun; Bruce L Horowitz; Konstantin N Konstantinov; Marc Barry; Joanna R Fair; Larry Massie; Antonios H Tzamaloukas
Journal:  World J Nephrol       Date:  2014-11-06

4.  UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.

Authors:  Naeem Bhojani; Jennifer Bjazevic; Brendan Wallace; Linda Lee; Kamaljot S Kaler; Marie Dion; Andrea Cowan; Nabil Sultan; Ben H Chew; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

5.  Vitamin B6 intake and the risk of incident kidney stones.

Authors:  Pietro Manuel Ferraro; Eric N Taylor; Giovanni Gambaro; Gary C Curhan
Journal:  Urolithiasis       Date:  2017-07-03       Impact factor: 3.436

6.  Vitamin B6 metabolites in idiopathic calcium stone formers: no evidence for a link to hyperoxaluria.

Authors:  Agnes Kaelin; Jean-Paul Casez; Philippe Jaeger
Journal:  Urol Res       Date:  2003-11-20

Review 7.  Medical and alternative therapies in urinary tract stone disease.

Authors:  Ercan Yuvanc; Erdal Yilmaz; Devrim Tuglu; Ertan Batislam
Journal:  World J Nephrol       Date:  2015-11-06

8.  Drosophila melanogaster as a function-based high-throughput screening model for antinephrolithiasis agents in kidney stone patients.

Authors:  Sohrab N Ali; Thamara K Dayarathna; Aymon N Ali; Tijani Osumah; Mohamed Ahmed; Tyler T Cooper; Nicholas E Power; Dongxing Zhang; Dajung Kim; Rachel Kim; Andre St Amant; Jinqiang Hou; Thomas Tailly; Jun Yang; Len Luyt; Paul A Spagnuolo; Jeremy P Burton; Hassan Razvi; Hon S Leong
Journal:  Dis Model Mech       Date:  2018-11-16       Impact factor: 5.758

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.